You are here

Omecamtiv Mecarbil

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv

FDA turns down Cytokinetics’ once-promising heart failure drug omecamtiv

Fierce Pharma

complete response letter

Omecamtiv Mecarbil

Flag link:

FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use

FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use

Fierce Biotech

Omecamtiv Mecarbil

Flag link:

Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug

Ahead of adcomm, FDA raises uncertainties on benefit-risk profile of Cytokinetics' potential heart drug

Endpoints

Omecamtiv Mecarbil

Flag link:

Cytokinetics aims to become the Vertex of cardiovascular disease

Cytokinetics aims to become the Vertex of cardiovascular disease

EP Vantage

Omecamtiv Mecarbil

cardiovascular disease

Flag link:

Cytokinetics hopes to resurrect omecamtiv

Cytokinetics hopes to resurrect omecamtiv

EP Vantage

Omecamtiv Mecarbil

Flag link:

Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect

Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect

Fierce Biotech

Omecamtiv Mecarbil

Ji Xing Pharmaceuticals

Flag link:

ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure

Fierce Biotech

Omecamtiv Mecarbil

Flag link:

AHA 2020 – look out for the omecamtiv fault lines

AHA 2020 – look out for the omecamtiv fault lines

EP Vantage

Omecamtiv Mecarbil

Flag link:

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

Amgen and Cytokinetics claim heart drug success, but results widely disappoint

BioPharma Dive

clinical trials

Omecamtiv Mecarbil

cardiovascular disease

Flag link:

Trial of Amgen, Servier’s heart failure drug clears interim check

Trial of Amgen, Servier’s heart failure drug clears interim check

PM Live

chronic heart failure

Omecamtiv Mecarbil

clinical trials

Flag link:

Amgen heart drug passes interim check, setting up year-end readout

Amgen heart drug passes interim check, setting up year-end readout

BioPharma Dive

Omecamtiv Mecarbil

Flag link:

Amgen, Servier heart failure drug clears trial hurdle

Amgen, Servier heart failure drug clears trial hurdle

PM Live

Omecamtiv Mecarbil

clinical trials

Flag link:

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure

Pharmaceutical Business Review

heart failure with reduced ejection fraction

Omecamtiv Mecarbil

Flag link:

Cytokinetics inches forward with heart failure program

Cytokinetics inches forward with heart failure program

BioPharma Dive

Omecamtiv Mecarbil

Flag link:

The 3 Most Important Drugs in Amgen's Pipeline

The 3 Most Important Drugs in Amgen's Pipeline

Motley Fool

Omecamtiv Mecarbil

Flag link:

Amgen, Cytokinetics heart failure drug succeeds in mid-stage study

Amgen, Cytokinetics heart failure drug succeeds in mid-stage study

Yahoo/Reuters

Omecamtiv Mecarbil

chronic heart failure

Flag link:

Cytokinetics Still Has Value, Despite Setbacks

Cytokinetics Still Has Value, Despite Setbacks

Seeking Alpha

Omecamtiv Mecarbil

Flag link:

Cytokinetics: 2014 Will Bring Critical Data Readouts On Tirasemtiv And Omecamtiv Mecarbil

Cytokinetics: 2014 Will Bring Critical Data Readouts On Tirasemtiv And Omecamtiv Mecarbil

Seeking Alpha

Omecamtiv Mecarbil

Flag link:

Fallout From This Heart-Drug Failure

Fallout From This Heart-Drug Failure

Motley Fool

Omecamtiv Mecarbil

Flag link:

Cheers and Jeers for Amgen's Pipeline

Cheers and Jeers for Amgen's Pipeline

Motley Fool

Omecamtiv Mecarbil

Flag link:

Pages